BioSpace News Archive

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced that BASES, a Nielsen Global Consumer business division, has named LUMIFY® redness reliever eye drops to its 2020 U.S. BASES Top 25 Breakthrough Innovations List in the “Superstar” category for its success in driving sales and category growth.

VYNE Therapeutics Inc. announced that its novel ZILXI™ topical foam, 1.5% will be available on October 1, 2020 by prescription for the treatment of inflammatory lesions of rosacea in adults.

Humana Inc. announced details of its 2021 Medicare product offerings, including Medicare Advantage and Prescription Drug Plans that are built with the benefits and options people eligible for Medicare need most.

exoSTING is engineered to provide targeted delivery of Codiak’s proprietary STING agonist to antigen presenting cells in the tumor microenvironment

Korro Bio strengthens board of directors with appointment of industry leader, Omar Khwaja, M.D., Ph.D.

Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced it has entered into a $25.0 million senior secured term loan with MidCap Financial Trust, as agent, and Silicon Valley Bank.

insitro, a machine-learning driven drug discovery and development company, announced the appointment of Roger Perlmutter, M.D., Ph.D., executive vice president and president of Merck Research Laboratories, Merck’s global R&D organization, as the company’s first independent board director.

Funding Will Support Clinical Trials to Evaluate the Company’s Novel Treatment for Peripheral Artery Disease

BIAL Biotech to be based in Cambridge, Massachusetts and will be a Research Center of Excellence dedicated to genetically-defined Parkinson’s disease

Sage Therapeutics, Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced the addition of Barry Greene to the company’s board of directors.